Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans (original) (raw)

References

  1. Kirn, D. H. & Thorne, S. H. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nature Rev. Cancer 9, 64–71 (2009)
    Article CAS Google Scholar
  2. Parato, K. A., Senger, D., Forsyth, P. A. & Bell, J. C. Recent progress in the battle between oncolytic viruses and tumours. Nature Rev. Cancer 5, 965–976 (2005)
    Article CAS Google Scholar
  3. Liu, T. C., Galanis, E. & Kirn, D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat. Clin. Pract. Oncol. 4, 101–117 (2007)
    Article CAS PubMed Google Scholar
  4. Vanderplasschen, A., Hollinshead, M. & Smith, G. L. Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. J. Gen. Virol. 78, 2041–2048 (1997)
    Article CAS PubMed Google Scholar
  5. Vanderplasschen, A., Mathew, E., Hollinshead, M., Sim, R. B. & Smith, G. L. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc. Natl Acad. Sci. USA 95, 7544–7549 (1998)
    Article ADS CAS PubMed PubMed Central Google Scholar
  6. Wein, L. M., Wu, J. T. & Kirn, D. H. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res. 63, 1317–1324 (2003)
    CAS PubMed Google Scholar
  7. Smith, G. L., Murphy, B. J. & Law, M. Vaccinia virus motility. Annu. Rev. Microbiol. 57, 323–342 (2003)
    Article CAS PubMed Google Scholar
  8. Katsafanas, G. C. & Moss, B. Vaccinia virus intermediate stage transcription is complemented by Ras-GTPase-activating protein SH3 domain-binding protein (G3BP) and cytoplasmic activation/proliferation-associated protein (p137) individually or as a heterodimer. J. Biol. Chem. 279, 52210–52217 (2004)
    Article CAS PubMed Google Scholar
  9. Yang, H. et al. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J. Clin. Invest. 115, 379–387 (2005)
    Article CAS PubMed PubMed Central Google Scholar
  10. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000)
    Article CAS PubMed Google Scholar
  11. Mastrangelo, M. J. et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 6, 409–422 (1999)
    Article CAS PubMed Google Scholar
  12. Kim, J. H. et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol. Ther. 14, 361–370 (2006)
    Article CAS PubMed Google Scholar
  13. Buller, R. M., Smith, G. L., Cremer, K., Notkins, A. L. & Moss, B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 317, 813–815 (1985)
    Article ADS CAS PubMed Google Scholar
  14. Park, B. H. et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 9, 533–542 (2008)
    Article CAS PubMed Google Scholar
  15. Hovgaard, D., Mortensen, B. T., Schifter, S. & Nissen, N. I. Clinical pharmacokinetic studies of a human haemopoietic growth factor, GM-CSF. Eur. J. Clin. Invest. 22, 45–49 (1992)
    Article CAS PubMed Google Scholar
  16. Choi, H. et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J. Clin. Oncol. 25, 1753–1759 (2007)
    Article PubMed Google Scholar
  17. Byrne, M. J. & Nowak, A. K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann. Oncol. 15, 257–260 (2004)
    Article CAS PubMed Google Scholar
  18. Moss, B. Vaccinia virus: a tool for research and vaccine development. Science 252, 1662–1667 (1991)
    Article ADS CAS PubMed Google Scholar
  19. Davis, M. E. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067–1070 (2010)
    Article ADS CAS PubMed PubMed Central Google Scholar
  20. Peng, K. W. et al. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 62, 4656–4662 (2002)
    CAS PubMed Google Scholar
  21. McCart, J. A. et al. Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. Mol. Ther. 10, 553–561 (2004)
    Article CAS PubMed Google Scholar
  22. Msaouel, P. et al. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol. Ther. 17, 2041–2048 (2009)
    Article CAS PubMed PubMed Central Google Scholar
  23. McCart, J. A. et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 61, 8751–8757 (2001)
    CAS PubMed Google Scholar
  24. Thorne, S. H. et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J. Clin. Invest. 117, 3350–3358 (2007)
    Article CAS PubMed PubMed Central Google Scholar
  25. Thorne, S. H. et al. Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy. Mol. Ther. 18, 1698–1705 (2010)
    Article CAS PubMed PubMed Central Google Scholar
  26. Rozen, S. & Skaletsky, H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol. Biol. 132, 365–386 (2000)
    CAS PubMed Google Scholar
  27. Kulesh, D. A. et al. Smallpox and pan-orthopox virus detection by real-time 3′-minor groove binder TaqMan assays on the Roche LightCycler and the Cepheid Smart Cycler platforms. J. Clin. Microbiol. 42, 601–609 (2004)
    Article CAS PubMed PubMed Central Google Scholar
  28. Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92, 205–216 (2000)
    Article CAS PubMed Google Scholar
  29. Choi, H. et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am. J. Roentgenol. 183, 1619–1628 (2004)
    Article PubMed Google Scholar
  30. Myers, J. L. W. & Arnold, D. Research Design and Statistical Analysis. 2nd edn, 505–512 (Laurence Erlbaum, 2003)
    Book Google Scholar

Download references

Acknowledgements

Jennerex Inc. was involved in the study design, data monitoring, analysis and interpretation, and in writing and submission of the report for publication. Jennerex Inc. funded the clinical study. Translational work was supported by grants to J.B. from the Terry Fox Foundation and the Canadian Institute for Health Research (CIHR) and by grants to T.-H.H. from the Korea Healthcare technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea (A091047). N.D.S. is supported by a Vanier Scholarship. C.J.B. was supported by a Natural Sciences and Engineering Research Council of Canada (NSERC) studentship. L.E. is supported by Ontario Graduate Scholarships in Science and Technology (OGSST). F.L.B. is supported by a Canadian Institutes of Health Research/Small and Medium Enterprises (CIHR/SME) Collaborative Research Program Fellowship. A.F. and J.C.B. are supported by Ontario Institute for Cancer Research.

Author information

Author notes

  1. James Burke
    Present address: Present address: Jennerex Inc., 450 Sansome Street, 16th floor, San Francisco, California 94111, USA.,
  2. John C. Bell and David H. Kirn: These authors contributed equally to this work.

Authors and Affiliations

  1. Jennerex Inc., 450 Sansome Street, 16th floor, San Francisco, 94111, California, USA
    Caroline J. Breitbach, Anne Moon, Adina Pelusio, Terri Robertson & David H. Kirn
  2. Department of Hematology/Oncology, 801 North 29th Street, Billings Clinic, Billings, 59101, Montana, USA
    James Burke & Jorge Nieva
  3. Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, Ontario K1H 8L6, Canada
    Derek Jonker, Laura Q. M. Chow, Fabrice Le Boeuf, Joe Burns, Laura Evgin, Naomi De Silva, Sara Cvancic, Kelley Parato, Jean-Simon Diallo, Manijeh Daneshmand & John C. Bell
  4. University of Ottawa, 75 Laurier Avenue East, Ottawa, Ontario K1N 6N5, Canada
    Derek Jonker, Laura Q. M. Chow, Joe Burns, Laura Evgin, Naomi De Silva, Sara Cvancic, Manijeh Daneshmand & John C. Bell
  5. Cancer Centers of the Carolinas, 3 Butternut Drive, Greenville, 29605, South Carolina, USA
    Joe Stephenson
  6. University of Pennsylvania Medical Center, 3400 Spruce Street, Philadelphia, 19104, Pennsylvania, USA
    Andrew R. Haas
  7. Pusan National University, Jangjeon-dong GeumJeong-gu, Busan 609-735, South Korea
    Tae-Ho Hwang, Ji-Eun Je & Yeon-Sook Lee
  8. RadMD, 712 Hyde Park, Doylestown, 18901, Pennsylvania, USA
    Richard Patt
  9. Robarts Research Institute, 100 Perth Drive, P.O. Box 5015, London, Ontario N6A 5K8, Canada
    Aaron Fenster

Authors

  1. Caroline J. Breitbach
    You can also search for this author inPubMed Google Scholar
  2. James Burke
    You can also search for this author inPubMed Google Scholar
  3. Derek Jonker
    You can also search for this author inPubMed Google Scholar
  4. Joe Stephenson
    You can also search for this author inPubMed Google Scholar
  5. Andrew R. Haas
    You can also search for this author inPubMed Google Scholar
  6. Laura Q. M. Chow
    You can also search for this author inPubMed Google Scholar
  7. Jorge Nieva
    You can also search for this author inPubMed Google Scholar
  8. Tae-Ho Hwang
    You can also search for this author inPubMed Google Scholar
  9. Anne Moon
    You can also search for this author inPubMed Google Scholar
  10. Richard Patt
    You can also search for this author inPubMed Google Scholar
  11. Adina Pelusio
    You can also search for this author inPubMed Google Scholar
  12. Fabrice Le Boeuf
    You can also search for this author inPubMed Google Scholar
  13. Joe Burns
    You can also search for this author inPubMed Google Scholar
  14. Laura Evgin
    You can also search for this author inPubMed Google Scholar
  15. Naomi De Silva
    You can also search for this author inPubMed Google Scholar
  16. Sara Cvancic
    You can also search for this author inPubMed Google Scholar
  17. Terri Robertson
    You can also search for this author inPubMed Google Scholar
  18. Ji-Eun Je
    You can also search for this author inPubMed Google Scholar
  19. Yeon-Sook Lee
    You can also search for this author inPubMed Google Scholar
  20. Kelley Parato
    You can also search for this author inPubMed Google Scholar
  21. Jean-Simon Diallo
    You can also search for this author inPubMed Google Scholar
  22. Aaron Fenster
    You can also search for this author inPubMed Google Scholar
  23. Manijeh Daneshmand
    You can also search for this author inPubMed Google Scholar
  24. John C. Bell
    You can also search for this author inPubMed Google Scholar
  25. David H. Kirn
    You can also search for this author inPubMed Google Scholar

Contributions

Study design: D.H.K. and J.C.B. Data analysis and study write-up: C.J.B., D.H.K., T.-H.H., A.M., R.P., A.P., T.R., J.C.B. and A.F. Enrolment and management of patients: J.B., D.J., J.S., A.R.H., L.Q.M.C. and J.N. Laboratory work: F.L.B., J.B., N.D.S., S.C., J.-E.J., L.E., Y.-S.L., K.P., J.S.D., M.D. and J.-S.D. C.J.B. and D.H.K. had access to all the data in the trial. C.J.B. and D.H.K. took the final decision to submit for publication.

Corresponding author

Correspondence toDavid H. Kirn.

Ethics declarations

Competing interests

C.J.B., J.B., A.M., A.P., T.R. and D.H.K. are employees of Jennerex Inc. and hold stock options in Jennerex Inc. T.-H.H. and J.C.B. consult for and hold stock options in Jennerex Inc. R.P., Y.-S.L. and M.D. consult for Jennerex Inc.

Supplementary information

Supplementary Information

The file contains Supplementary Figures 1-4 with legends, a Supplementary Discussion and Supplementary References. (PDF 636 kb)

Supplementary Movie 1

This movie shows the 360° view of a colorectal carcinoma tumour in which vaccinia (JX-594) antigens were detected by immunohistochemistry. Green staining represents areas of tumour staining for vaccinia (JX-594). (MOV 1573 kb)

PowerPoint slides

Rights and permissions

About this article

Cite this article

Breitbach, C., Burke, J., Jonker, D. et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.Nature 477, 99–102 (2011). https://doi.org/10.1038/nature10358

Download citation